🎉 M&A multiples are live!
Check it out!

ITeos Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for ITeos Therapeutics and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

ITeos Therapeutics Overview

About ITeos Therapeutics

ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.


Founded

2019

HQ

United States of America
Employees

173

Financials

LTM Revenue $27.1M

LTM EBITDA -$161M

EV

-$278M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

ITeos Therapeutics Financials

ITeos Therapeutics has a last 12-month revenue of $27.1M and a last 12-month EBITDA of -$161M.

In the most recent fiscal year, ITeos Therapeutics achieved revenue of $35.0M and an EBITDA of -$153M.

ITeos Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See ITeos Therapeutics valuation multiples based on analyst estimates

ITeos Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $12.6M $35.0M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$144M -$153M XXX XXX XXX
EBITDA Margin -1143% -437% XXX XXX XXX
Net Profit $96.7M -$113M XXX XXX XXX
Net Margin 767% -322% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

ITeos Therapeutics Stock Performance

As of April 15, 2025, ITeos Therapeutics's stock price is $6.

ITeos Therapeutics has current market cap of $211M, and EV of -$278M.

See ITeos Therapeutics trading valuation data

ITeos Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$278M $211M XXX XXX XXX XXX $-3.52

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

ITeos Therapeutics Valuation Multiples

As of April 15, 2025, ITeos Therapeutics has market cap of $211M and EV of -$278M.

ITeos Therapeutics's trades at -10.3x LTM EV/Revenue multiple, and 1.7x LTM EBITDA.

Analysts estimate ITeos Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for ITeos Therapeutics and 10K+ public comps

ITeos Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$278M XXX XXX XXX
EV/Revenue -8.0x XXX XXX XXX
EV/EBITDA 1.8x XXX XXX XXX
P/E -1.6x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 2.8x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get ITeos Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

ITeos Therapeutics Valuation Multiples

ITeos Therapeutics's NTM/LTM revenue growth is -70%

ITeos Therapeutics's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $1.1M for the same period.

Over next 12 months, ITeos Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate ITeos Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for ITeos Therapeutics and other 10K+ public comps

ITeos Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 178% XXX XXX XXX XXX
EBITDA Margin -437% XXX XXX XXX XXX
EBITDA Growth 6% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -508% XXX XXX XXX XXX
Revenue per Employee $0.2M XXX XXX XXX XXX
Opex per Employee $1.1M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 140% XXX XXX XXX XXX
R&D Expenses to Revenue 416% XXX XXX XXX XXX
Opex to Revenue 541% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

ITeos Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Vaccines & Immunotherapies comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

ITeos Therapeutics M&A and Investment Activity

ITeos Therapeutics acquired  XXX companies to date.

Last acquisition by ITeos Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . ITeos Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by ITeos Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About ITeos Therapeutics

When was ITeos Therapeutics founded? ITeos Therapeutics was founded in 2019.
Where is ITeos Therapeutics headquartered? ITeos Therapeutics is headquartered in United States of America.
How many employees does ITeos Therapeutics have? As of today, ITeos Therapeutics has 173 employees.
Who is the CEO of ITeos Therapeutics? ITeos Therapeutics's CEO is Dr. Michel Detheux, PhD.
Is ITeos Therapeutics publicy listed? Yes, ITeos Therapeutics is a public company listed on NAS.
What is the stock symbol of ITeos Therapeutics? ITeos Therapeutics trades under ITOS ticker.
When did ITeos Therapeutics go public? ITeos Therapeutics went public in 2020.
Who are competitors of ITeos Therapeutics? Similar companies to ITeos Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of ITeos Therapeutics? ITeos Therapeutics's current market cap is $211M
What is the current revenue of ITeos Therapeutics? ITeos Therapeutics's last 12-month revenue is $27.1M.
What is the current EBITDA of ITeos Therapeutics? ITeos Therapeutics's last 12-month EBITDA is -$161M.
What is the current EV/Revenue multiple of ITeos Therapeutics? Current revenue multiple of ITeos Therapeutics is -10.3x.
What is the current EV/EBITDA multiple of ITeos Therapeutics? Current EBITDA multiple of ITeos Therapeutics is 1.7x.
What is the current revenue growth of ITeos Therapeutics? ITeos Therapeutics revenue growth between 2023 and 2024 was 178%.
Is ITeos Therapeutics profitable? Yes, ITeos Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.